Oligo-recurrence from anaplastic lymphoma kinase-rearranged lung adenocarcinoma
نویسندگان
چکیده
منابع مشابه
Drug resistance in anaplastic lymphoma kinase‐rearranged lung cancer
The anaplastic lymphoma kinase (ALK) gene encodes a receptor tyrosine kinase, and many kinds of ALK fusion genes have been found in a variety of carcinomas. There is almost no detectable expression of ALK in adults. However, through ALK gene rearrangement, the resultant ALK fusion protein is aberrantly overexpressed and dimerized through the oligomerization domains, such as the coiled-coil doma...
متن کاملHemorrhagic Brain Metastases in a Patient with Anaplastic Lymphoma Kinase (ALK)-Rearranged Invasive Mucinous Adenocarcinoma of the Lung
BACKGROUND Invasive mucinous adenocarcinoma (IMA) is a rare variant of adenocarcinoma of the lung. It frequently shows KRAS mutations, while ALK rearrangement is exceedingly rare. We present a case of ALK-rearranged IMA of the lung presenting with an unusual pattern of brain metastases, radiologically mimicking a cavernous angioma. CASE REPORT A 44-year-old non-smoker female was first diagnosed...
متن کاملCeritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma.
The anaplastic lymphoma kinase (ALK) gene is expressed in.50% of anaplastic large-cell lymphomas (ALCLs). Although most patients withALK-positiveALCL respondwell to anthracycline-based chemotherapy, relapses do occur (5-year failure-free survival 60%) and require salvage therapy, generally with poor outcomes. Autologous stem cell transplant is an option in the salvage setting, but not all patie...
متن کاملControl of brain metastases with alectinib in anaplastic lymphoma kinase‐rearranged lung cancer
Brain metastasis from non-small cell lung cancer remains a challenge to physicians. It occurs in 30% of patients with advanced stage adenocarcinoma of lung and is often regarded as the ominous sign of disease progression and death. Alectinib is likely to be a promising agent, even after the failure of crizotinib and ceritinib, for patients with anaplastic lymphoma kinase (ALK) -driven non-small...
متن کاملP-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer
The anaplastic lymphoma kinase (ALK) fusion oncogene is observed in 3%-5% of non-small cell lung cancer (NSCLC). Crizotinib and ceritinib, a next-generation ALK tyrosine kinase inhibitor (TKI) active against crizotinib-refractory patients, are clinically available for the treatment of ALK-rearranged NSCLC patients, and multiple next-generation ALK-TKIs are currently under clinical evaluation. T...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Advances in Respiratory Medicine
سال: 2019
ISSN: 2543-6031,2451-4934
DOI: 10.5603/arm.2019.0053